For much of the past decade, success in the cannabis and psychedelic sectors has been measured by one metric above almost all others: the ability to raise capital.
Funding announcements became synonymous with momentum. Larger financing rounds, higher valuations and ambitious expansion plans were often viewed as evidence that an industry was progressing towards mainstream acceptance. Investors largely focused on clinical milestones, regulatory reform and commercial growth, confident that public listings or strategic acquisitions would eventually provide an opportunity to realise returns.
That conversation is beginning to change.
As both industries mature, investors are increasingly asking a different question. Rather than focusing solely on how companies raise money, attention is shifting towards how capital ultimately finds its way back out. In other words, liquidity is emerging as one of the defining issues that will shape the next phase of growth for cannabis and psychedelic medicine.
Across both sectors, billions of dollars have been invested into research, pharmaceutical manufacturing, cultivation, intellectual property, clinical infrastructure and healthcare delivery. Early investors have supported businesses through multiple funding rounds, often over many years, expecting that an IPO or acquisition would eventually provide a clear exit.
For many, those exits have taken far longer than anticipated.
The cannabis industry provides the clearest example of how quickly investor expectations can evolve.
When Canada legalised recreational cannabis, capital poured into the sector at an unprecedented pace. Public companies achieved extraordinary valuations, investors competed aggressively for exposure and new operators entered the market almost weekly. The prevailing assumption was that global legalisation would follow a similar trajectory, creating one of the world’s fastest-growing consumer industries.
Commercial reality proved considerably more complex.
Oversupply, pricing pressure, fragmented regulations and slower-than-expected international expansion fundamentally reshaped investor sentiment. Public market valuations contracted sharply, access to capital became more selective and many businesses were forced to restructure in pursuit of profitability rather than growth at any cost.
Despite those challenges, the underlying industry continued to mature.
Many operators invested heavily in pharmaceutical-grade manufacturing, expanded export capabilities, strengthened compliance systems and built intellectual property capable of supporting long-term growth. The industry’s operational foundations became significantly stronger, even as public market enthusiasm declined.
What changed was not the quality of every business, but the availability of liquidity.
Recent transactions suggest the market is now entering a more mature phase.
One of the most significant deals over the past year was Organigram’s acquisition of Germany’s Sanity Group, reflecting growing confidence in Europe’s regulated medical cannabis market while providing an exit pathway for existing shareholders. Across North America, consolidation has accelerated as larger operators acquire strategically valuable businesses to build scale, improve operational efficiency and enter new markets more quickly than would be possible through organic expansion.
The acquisition of cannabis delivery platform Eaze by Vireo Health offered another important lesson. Eaze was once valued at approximately US$700 million during the industry’s investment boom, yet was ultimately acquired at a substantially lower valuation. While the transaction highlighted the dramatic market reset that has occurred, it also reinforced an important reality: investors and founders still require liquidity, even when valuations fall. Strategic acquisitions remain one of the most practical mechanisms for capital to be recycled back into the market.
The psychedelic medicines sector is now approaching a similar, albeit fundamentally different, stage of development.
Unlike cannabis, psychedelic medicine is driven primarily by clinical research rather than consumer demand. Commercial success depends on regulatory approval, robust clinical evidence, physician adoption and reimbursement within healthcare systems. Those milestones inevitably require longer development timelines than many traditional healthcare businesses.
Investors entering psychedelic biotechnology companies generally understand this reality. Developing novel therapies can take many years, with significant regulatory hurdles and substantial capital requirements along the way.
However, extended development cycles also increase the importance of efficient capital markets.
Founders, early employees and seed investors may spend a decade building meaningful equity positions before any traditional exit opportunity emerges. Venture funds nearing the end of their investment lifecycle may require liquidity regardless of whether a company continues to perform well, while prospective investors may become more cautious if realistic exit pathways remain uncertain.
Capital continues to flow into the sector, but it has become considerably more discerning.
Rather than supporting dozens of speculative businesses, institutional investors are increasingly concentrating funding on companies with advanced clinical programmes, experienced management teams and credible regulatory strategies. Larger financing rounds completed by leading developers demonstrate that high-quality assets continue to attract investment, while smaller companies face a much more demanding fundraising environment.
At the same time, mergers and acquisitions are gradually becoming a more meaningful feature of the psychedelic ecosystem. Pharmaceutical companies, specialist biotechnology investors and strategic acquirers are increasingly evaluating opportunities to acquire intellectual property, clinical programmes and experienced development teams rather than building those capabilities internally.
Although transaction volumes remain modest compared with more established pharmaceutical sectors, they point towards a market beginning to develop more sophisticated liquidity pathways.
This evolution mirrors a broader shift occurring across global private capital markets.
Companies in many industries are remaining private for longer than previous generations. Larger private funding rounds have reduced reliance on early public listings, while heightened regulatory expectations and volatile equity markets have encouraged businesses to delay IPOs until they reach greater scale and maturity.
Remaining private offers significant advantages.
Management teams can focus on long-term execution rather than quarterly reporting cycles, clinical programmes can progress without the constant pressure of public market expectations, and companies gain greater flexibility to refine commercial strategies before entering listed markets.
However, longer private ownership creates a significant challenge.
Capital becomes increasingly illiquid.
Founders, employees and early investors may hold valuable equity for many years without practical opportunities to convert those holdings into realised returns. Even highly successful businesses can struggle to attract additional investment if prospective investors cannot clearly identify how and when liquidity is likely to occur.
This is where secondary markets may become one of the most important developments for both industries.
Historically, secondary transactions occupied a relatively small niche within venture capital, providing occasional liquidity for founders or early employees while companies remained private.
Today, secondaries are becoming an increasingly important component of sophisticated capital markets.
Rather than forcing companies towards premature IPOs, secondary transactions allow existing shareholders to sell part of their holdings to new investors while the business continues growing. This enables fresh capital to enter mature private companies without disrupting long-term strategic plans, while rewarding those who provided early-stage funding.
For industries characterised by lengthy commercialisation timelines, this model has particular relevance.
Psychedelic biotechnology companies often require years of clinical development before generating meaningful revenue. Carefully structured secondary transactions could allow specialist healthcare investors to acquire positions in promising businesses while providing liquidity for founders, employees and early venture investors.
Likewise, mature medicinal cannabis companies with stable operations but limited public market interest may find private secondary transactions an attractive alternative to repeated equity raises or premature public listings.
Liquidity should not be viewed as a sign that investors are losing confidence.
In many cases, it represents the natural evolution of a maturing industry.
Healthy capital markets require efficient mechanisms that allow investment to move between different classes of investors. Early-stage venture funds, family offices, institutional investors, pension funds and strategic corporate buyers all operate with different investment horizons and return objectives. Secondary markets and strategic acquisitions help connect those participants by allowing capital to be recycled into the next generation of innovation.
That recycling of capital may ultimately strengthen both industries.
Investors who achieve successful exits are more likely to back future companies. Institutional participation often increases confidence throughout the broader market, while entrepreneurs benefit from deeper pools of available capital capable of supporting increasingly ambitious research and commercialisation programmes.
Australia offers an interesting case study in how this evolution may unfold.
The country’s medicinal cannabis industry has matured rapidly over the past decade, supported by expanding patient access, GMP manufacturing, increasing export activity and stronger clinical adoption. At the same time, Australia’s regulated prescribing pathway for MDMA and psilocybin has positioned the country at the forefront of psychedelic medicine, attracting growing interest from biotechnology companies, specialist clinics, researchers and international investors.
Australia also benefits from an established biotechnology investment ecosystem through the ASX, alongside sophisticated healthcare investors with experience funding long-term clinical development. As psychedelic medicine progresses towards broader commercialisation, that combination of regulatory leadership and capital market expertise may provide Australian companies with a meaningful competitive advantage.
As both sectors continue to evolve, investors are likely to place greater emphasis on governance, financial sustainability, clinical execution and credible pathways towards liquidity than on headline valuations alone.
Companies that recognise these changing expectations early may be better positioned to attract long-term capital.
Scientific breakthroughs, regulatory reform and pharmaceutical innovation will remain essential foundations for both cannabis and psychedelic medicine. Yet history suggests that successful industries are built on more than technological progress alone. They also require capital markets capable of efficiently supporting businesses throughout every stage of their development.
The next decade is therefore unlikely to be defined solely by who raises the largest funding rounds or achieves the highest valuations.
Instead, it may be remembered as the period in which cannabis and psychedelic medicine evolved into mature healthcare sectors supported by increasingly sophisticated financial ecosystems. Recent acquisitions, continued consolidation across medicinal cannabis, stronger fundraising for high-quality psychedelic companies and the gradual emergence of strategic buyers all point towards the same conclusion.
Scientific innovation may create new industries, but functioning capital markets determine whether those industries mature.
For investors, founders and entrepreneurs alike, liquidity is no longer a financial footnote. It is becoming one of the sector’s most important strategic advantages.
